SCHEMBL304796

SCHEMBL304796

CCOC(=O)C(=O)CCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.54
ALDH1A1 P00352 1/20 0.53
KEAP1 Q14145 1/20 0.52
KMT2A Q03164 2/20 0.50
ABCB1 P08183 1/20 0.50
MEN1 O00255 1/20 0.50
PLAAT5 Q96KN8 2/20 0.49
PLAAT4 Q9UL19 2/20 0.49
MAPT P10636 2/20 0.49
PLAAT3 P53816 1/20 0.49
PLAAT2 Q9NWW9 1/20 0.49
CYP4F2 P78329 1/20 0.49
CYP4A11 Q02928 1/20 0.49
FFAR1 O14842 1/20 0.48
ALOX5 P09917 1/20 0.48
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alcohol SCHEMBL28404120 0.97 L3MBTL1 (0.52) L3MBTL1TDP1SMN1; SMN2ALDH1A1KEAP1
SCHEMBL1858472 0.90 ALOX5 (0.56) L3MBTL1TDP1SMN1; SMN2PLAAT5PLAAT4
SCHEMBL304577 0.89 L3MBTL1 (0.55) L3MBTL1TDP1SMN1; SMN2ALDH1A1KEAP1
SCHEMBL304579 0.89 L3MBTL1 (0.55) L3MBTL1TDP1SMN1; SMN2ALDH1A1KEAP1
SCHEMBL7635946 0.88 ALOX5 (0.55) L3MBTL1SMN1; SMN2PLAAT5PLAAT4MAPT
SCHEMBL7330817 0.88 FFAR1 (0.62) PLAAT5PLAAT4PLAAT3PLAAT2FFAR1
SCHEMBL9725829 0.87 FFAR1 (0.65) L3MBTL1TDP1ALDH1A1FFAR1ALOX5
SCHEMBL1107673 0.87 SMN1; SMN2 (0.52) L3MBTL1TDP1SMN1; SMN2ALDH1A1KEAP1
SCHEMBL8816730 0.87 MAPT (0.57) SMN1; SMN2PLAAT5PLAAT4MAPTPLAAT3
SCHEMBL7640337 0.87 MAPT (0.57) SMN1; SMN2PLAAT5PLAAT4MAPTPLAAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 625 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119913221-A Method for synthesizing ethyl 2-N-benzylamino-4-phenylbutyrate by using enzymatic method 中国科学院天津工业生物技术研究所 2025-05-02 CN claimed
CN-117866221-A Super-stable hydrogen bond organic framework material for regenerating light-driven cofactor NADH, and synthesis method and application thereof 南京师范大学 2024-04-12 CN claimed
CN-115851641-A Fusion enzyme for efficiently producing (R) -2-hydroxy-4-phenylbutyric ethyl butyrate and application thereof 浙江工业大学 2023-03-28 CN claimed
CN-115820622-A Double-enzyme self-assembly compound and application of compound in synthesizing (R) -2-hydroxy-4-phenylbutyrate 浙江工业大学 2023-03-21 CN claimed
CN-109929885-B Method for preparing ethyl gamma-2-hydroxy-4-phenylbutyrate by coupling extraction of enzyme membrane reactor 江苏惠利生物科技有限公司 2022-07-15 CN claimed
CN-114574455-A Method for forming supramolecular hydrogel for biocatalysis by utilizing enzyme self-assembly 清华大学 2022-06-03 CN claimed
CN-114249795-A Preparation method of enalapril maleate and intermediate thereof 佛山奕安赛医药科技有限公司 2022-03-29 CN claimed
CN-111218441-B Magnetic immobilized yeast cell and application thereof in preparation of (R) -2-hydroxy-4-phenylbutyrate ethyl ester 浙江工业大学 2022-03-18 CN claimed
CN-109370994-B Carbonyl reductase mutant mut-AcCR (G152L/Y189N) and application and coding gene thereof 华南理工大学 2021-05-14 CN claimed
CN-112225778-A Preparation method of enalapril maleate 辰欣药业股份有限公司 2021-01-15 CN claimed
US-20070072278-A1 Using glucose dehydrogenase to asymmetrically reducing a 2-oxo-4-phenylbutyrate to produce a (R)-2-hydroxy-4-phenylbutyrate; industrial scale SUMITOMO CHEMICAL COMPANY LIMITED 2007-03-29 US claimed
EP-1762625-A1 Reductase gene and use thereof Sumitomo Chemical Company, Limited (JP) 2007-03-14 EP claimed
US-20050191735-A1 Oxidoreductase IEP GMBH (DE) 2005-09-01 US claimed
US-20040265978-A1 Enzymatic method for the enantioselective reduction of keto compounds IEP GMBH (DE) 2004-12-30 US claimed
EP-1437401-A1 Oxidoreductase Juelich Enzyme Products GmbH (DE) 2004-07-14 EP claimed
EP-1383899-A2 ENZYMATIC METHOD FOR THE ENANTIOSELECTIVE REDUCTION OF KETO COMPOUNDS Jülich Enzyme Products GmbH (DE) 2004-01-28 EP claimed
WO-2002086126-A2 ENZYMATIC METHOD FOR THE ENANTIOSELECTIVE REDUCTION OF KETO COMPOUNDS JUELICH ENZYME PRODUCTS GMBH (DE) 2002-10-31 WO claimed
US-5066801-A PREPARATION OF SULFONIC ACID ESTERS CIBA-GEIGY CORPORATION (US) 1991-11-19 US claimed
EP-0206993-B1 SULPHONIC-ACID ESTERS CIBA-GEIGY AG (CH) 1990-05-23 EP claimed
US-4785089-A Novel sulfonic acid esters and their preparation CIBA-GEIGY CORPORATION (US) 1988-11-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072278-A1 Using glucose dehydrogenase to asymmetrically reducing a 2-oxo-4-phenylbutyrate to produce a (R)-2-hydroxy-4-phenylbutyrate; industrial scale HADHB, HPD, PDHB L3MBTL1 157/4885TDP1 688/4885SMN1; SMN2 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.